Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm

Nature Medicine volume 9, pages 1449–1452 (2003)Cite this article

Scaling up access to antiretroviral drugs (ARVs) for HIV-infected adults and children in developing countries can no longer be refused for medical or economic reasons, or on the grounds of inequality, lack of infrastructure, risk of viral resistance or alternative priorities. Access to ARVs is an appropriate, rational and cost-effective investment choice in developing countries.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Observed source prices (1997–2002) for three ARVs and their generic substitutes, in US dollars, at monthly time of the transaction, when entering the country.
Figure 2: Official UNAIDS estimations of current funding availability and requirements to achieve an effective global response to the HIV/AIDS epidemic, as elaborated at the September 2003 United Nations General Assembly Session on HIV/AIDS1.

References

  1. Progress report on the global response to HIV/AIDS epidemic, 2003: follow-up to the 2001 United Nations General Assembly Session on HIV/AIDS. (UNAIDS, Geneva/New York, 2003).

  2. World Health Organization says failure to deliver AIDS medicines is a global health emergency. (WHO, Geneva/New York, 2003).

  3. Galvão, J. Lancet 360, 1862–1865 (2002).

    Article  Google Scholar 

  4. Wolff, M. et al. Rev. Med. Chile 129, 886–894 (2001).

    Article  CAS  Google Scholar 

  5. Cohen, J. Science 301, 1658–1662 (2003).

    Article  CAS  Google Scholar 

  6. Katzenstein, D., Laga, M. & Moatti, J.P. AIDS 17 (suppl. 3), S1–S4 (2003).

    Article  Google Scholar 

  7. Farmer, P. et al. Bull. World Health Organ. 79, 1145–1151 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Meda, N. et al. AIDS 13, 1397–1405 (2001).

    Article  Google Scholar 

  9. Levi, C. & Vitória, M.A.A. AIDS 16, 2373–2383 (2002).

    Article  Google Scholar 

  10. Kilian, A.H.D. et al. AIDS 13, 391–398 (1999).

    Article  CAS  Google Scholar 

  11. L'accès aux traitements du VIH/Sida en Côte d'Ivoire. Evaluation de l'Initiative Onusida/ministère de la Santé Publique. (eds. Msellati, P., Vidal, L. & Moatti, J.P.) 233–246 (ANRS, Coll. Sciences Sociales & Sida, Paris, 2001).

  12. Chakraborty, H. et al. AIDS 15, 621–627 (2001).

    Article  CAS  Google Scholar 

  13. Law, M.G., Prestage, G., Grulich, A., Van de Ven, P. & Kippax, S. AIDS 15, 1287–1294 (2001).

    Article  CAS  Google Scholar 

  14. Scheer, S., Chu, P.L., Klausner, J.D., Katz, M.H. & Schwarcz, S.K. Lancet 357, 432–435 (2001).

    Article  CAS  Google Scholar 

  15. Bouhnik, A.D. et al. J. Epidemiol. Commun. Health 56, 349–353 (2002).

    Article  Google Scholar 

  16. Guimaraes, M.D., Boschi-Pinto, C. & Castilho, E.A. Intl. J. STD AIDS 12, 334–341 (2001).

    Article  CAS  Google Scholar 

  17. Economics of AIDS and access to HIV/AIDS care in developing countries. Issues and challenges. (eds. Moatti, J.P. et al.) 121–165 (ANRS, Paris, 2003).

  18. Lopez-Casasnovas, G. & Puig-Junoy, J. Health Pol. 54, 87–123 (2000).

    Article  CAS  Google Scholar 

  19. WHO Essential Drugs and Medicines Policy. Pilot procurement quality and sourcing project: access to antimalarial, anti-tuberculosis and HIV/AIDS drugs and HIV/AIDS diagnostics of acceptable quality. (WHO, Geneva, 2002).

  20. Meeting of the Ministries of Health for a subregional observatory of HIV-related medicines and diagnostics. (ECOWAS/CEDEAO, Accra, 2002).

  21. Ainsworth, M. & Teokul, W. Lancet 356, 55–60 (2000).

    Article  CAS  Google Scholar 

  22. Creese, A., Floyd, K., Alban, A. & Guinness, L. Lancet 359, 1635–1642 (2002).

    Article  Google Scholar 

  23. Marseille, E., Hofmann P, B. & Kahn, K.G. Lancet 359, 1851–1856 (2002).

    Article  Google Scholar 

  24. Bozzette, S.A. et al. N. Engl. J. Med. 344, 817–823 (2001).

    Article  CAS  Google Scholar 

  25. Rosen, S. et al. Harv. Bus. Rev. 81, 80–87 (2003).

    PubMed  Google Scholar 

  26. Garber, A.M. in Handbook of Health Economics Vol. 1A (eds. Culyer, A.J. & Newhouse, J.P.) 181–221 (Elsevier Science, Amsterdam, 2000).

    Google Scholar 

  27. Freedberg, K.A. et al. N. Engl. J. Med. 344, 824–831 (2001).

    Article  CAS  Google Scholar 

  28. Skordis, J. & Nattrass, N. J. Health Econ. 21, 405–442 (2002).

    Article  Google Scholar 

  29. Boulle, A., Kenyon, C., Skordis, J. & Wood, R. S. Afr. Med. J. 92, 811–817 (2002).

    PubMed  Google Scholar 

  30. Over, M., Gupta, I. & Heywood, P. Antiretroviral therapy in India: issues and prospects. in Current Issues in the Economics of HIV/AIDS, (International AIDS and Economics Network (IAEN) Conference, Washington DC, 2003). http://www.iaea.org/files.cgi/10191_Mead-Over--IndiaART11_short.pdf

    Google Scholar 

  31. Scaling up antiretroviral therapy in resource limited settings. Guidelines for a public health approach. (WHO HIV/AIDS Department, Geneva, 2002).

  32. Dyer, G. Economic collapse in South Africa without action on AIDS. Financial Times 15 July 2003.

    Google Scholar 

  33. Wainberg, M. & Friedland, G. JAMA 279, 1977–1983 (1998).

    Article  CAS  Google Scholar 

  34. Carrieri, P. et al. J. AIDS 28, 232–239 (2001).

    CAS  Google Scholar 

  35. Hertogs, K. et al. AIDS 14, 1203–1210 (2000).

    Article  CAS  Google Scholar 

  36. Havlir, D., Vella, S. & Hammer, S. AIDS 16, S7–S9 (2002).

    Article  Google Scholar 

  37. Orrell, C., Bangsberg, D.R., Badri, M. & Wood, R. AIDS 17, 1369–1375 (2003).

    Article  Google Scholar 

  38. Harries, A.D., Nyangulu, D.S., Hargreaves, N.J., Kaluwa, O. & Salaniponi, F.M. Lancet 358, 410–414 (2001).

    Article  CAS  Google Scholar 

  39. Castro-Leal, F., Dayton, J., Demery, L. & Mehra, K. Bull. World Health Organ. 78, 66–74 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Schwartländer, B. et al. Science 292, 2434–2436 (2001).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Université de la Méditerrannée & INSERM Research Unit 379, Marseilles, 13008, France

    J P Moatti

  2. Programme National de Lutte contre le SIDA, Dakar, BP154, Sénégal

    I N'Doye

  3. Division of Infectious Diseases, Columbia University, New York, 10032, New York, USA

    S M Hammer

  4. Hôpital Européen Georges Pompidou, INSERM Research Unit 430, Paris, 75908, France

    P Hale

  5. Université René Descartes Paris V & Agence Nationale de Recherches sur le SIDA (ANRS), Paris, 75013, France

    M Kazatchkine

Authors
  1. J P Moatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I N'Doye
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S M Hammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Hale
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Kazatchkine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J P Moatti.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moatti, J., N'Doye, I., Hammer, S. et al. Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Nat Med 9, 1449–1452 (2003). https://doi.org/10.1038/nm1203-1449

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1203-1449

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing